Sanofi introduces Aubagio for MS treatment
Sanofi Genzyme, the specialty care global business unit of Sanofi, brings to India Aubagio, from its international Multiple Sclerosis (MS) portfolio. A chronic and debilitating disease of the nervous system, Multiple Sclerosis has varied symptoms like weakness in the limbs, poor vision, fatigue or slurred speech. Aubagio (Teriflunomide, 14 mg) is the first original ‘once-daily’ oral ‘disease modifying therapy’ (DMT) for Multiple Sclerosis to be approved in India. It offers an effective, safe and a convenient option that is indicated as a first-line treatment for relapsing forms of Multiple Sclerosis that must be taken once a day, with or without food. First approved by the US FDA in 2012, Aubagio has a strong global presence today with approvals in more than 81 countries. It has been extensively studied in more than 5,500 patients with up to 13 years of clinical and follow-up studies with proven clinical efficacy, safety and tolerability outcomes. Globally, more than 85,000 patients with Multiple Sclerosis are benefitting from the use of Aubagio.